Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 495 shares of the business's stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $150.74, for a total transaction of $74,616.30. Following the completion of the transaction, the chief financial officer now directly owns 76,312 shares in the company, valued at $11,503,270.88. This represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Michael Burkes Brophy also recently made the following trade(s):
- On Monday, April 21st, Michael Burkes Brophy sold 610 shares of Natera stock. The shares were sold at an average price of $145.55, for a total transaction of $88,785.50.
- On Monday, March 31st, Michael Burkes Brophy sold 2,562 shares of Natera stock. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42.
- On Monday, March 17th, Michael Burkes Brophy sold 792 shares of Natera stock. The shares were sold at an average price of $146.04, for a total value of $115,663.68.
- On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The stock was sold at an average price of $176.88, for a total value of $7,694,633.76.
- On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $719,046.45.
- On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The stock was sold at an average price of $176.60, for a total value of $333,067.60.
- On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The stock was sold at an average price of $161.87, for a total transaction of $233,416.54.
- On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08.
Natera Stock Performance
Shares of NTRA stock opened at $154.48 on Friday. Natera, Inc. has a 12-month low of $87.20 and a 12-month high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The firm has a market capitalization of $20.88 billion, a price-to-earnings ratio of -87.77 and a beta of 1.80. The business has a 50 day simple moving average of $148.26 and a 200 day simple moving average of $153.19.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.
Hedge Funds Weigh In On Natera
Several large investors have recently bought and sold shares of NTRA. Vanguard Group Inc. boosted its holdings in shares of Natera by 7.7% in the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock valued at $1,949,697,000 after acquiring an additional 879,463 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Natera by 134.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares during the period. JPMorgan Chase & Co. boosted its stake in Natera by 43.7% during the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares in the last quarter. Wellington Management Group LLP boosted its stake in Natera by 15.7% during the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after purchasing an additional 439,778 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Natera by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock valued at $355,809,000 after purchasing an additional 142,201 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.
Analyst Ratings Changes
NTRA has been the topic of several recent analyst reports. Morgan Stanley upped their target price on shares of Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. The Goldman Sachs Group upped their price target on Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. Sanford C. Bernstein lifted their price objective on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a report on Friday, January 10th. Canaccord Genuity Group reissued a "buy" rating and issued a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. Finally, StockNews.com upgraded Natera from a "sell" rating to a "hold" rating in a research report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and an average target price of $175.76.
Check Out Our Latest Report on Natera
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
